Coya Therapeutics 3Q 2026: Revenue $234.13K, EPS ($0.45) — 10-Q Summary
Coya Therapeutics reported 3Q 2026 revenue of $234.13K, down 93.4% YoY, and a net loss of $10.62M, up 401.8% YoY. The decline was due to lower collaboration revenue and higher R&D spending. The company completed enrollment for its COYA 302 ALS Phase 2/3 trial and received FDA Fast Track Designation. Coya expects its cash to last into 2H 2027.
How this was made
The 30-second read
Why it matters
The filing underscores heightened financial risk and may trigger short-term sell pressure, though the Fast Track designation could be a longer-term catalyst.
Market read
Micro-cap biotech investors will reassess exposure to Coya after the earnings miss and cash burn update.
What to watch
Cash runway into H2 2027 may provide enough liquidity for continued trial funding.
Background
Coya Therapeutics filed its 10-Q for Q3 2026, highlighting a steep revenue drop and increased R&D expenses tied to its ALS Phase 2/3 trial.
Ticker impact
10-Q shows revenue down 93% YoY and net loss widening to $10.6M, with higher R&D spend on ALS trial.
likely pressure as the market prices in the widened loss and revenue decline
First filing of the quarter reveals material financial deterioration and higher cash burn.
Market effects
Biotech sector may see broader risk aversion as small-cap ALS trials face funding pressures.
US biotech microcaps could experience modest sell pressure.
Limited to investors tracking early-stage biotech earnings.
Counterpoint
If the Fast Track designation leads to accelerated approval, the stock could rebound on future upside.
Key entities
- companyCoya Therapeutics, Inc.
Biotech firm developing ALS therapy COYA 302.
